无码乱码天天更新_日本丰满熟妇HD饥渴的少妇_欧美国产亚洲精品?第一页_久久五月天桃花_午夜国产福利免费一级视频_亚洲AV性色在线观看_日韩一二三四免费视频_丝袜足脚交91精品_av免费在线观看网址_国产热门精品第1页91

Cangzhou Dafeng Chemical Co., Ltd., formerly known as Suzhou Baishite Biotechnology Co., Ltd., was founded in 2015 with a registered capital of 5 million yuan. It is located in the Lingang Economic and Technological Development Zone (Beijing Biomedical Industry Park), a pharmaceutical and chemical park in Cangzhou City, Hebei Province. The company covers an area of 20000 square meters, including 615 square meters for workshops, 1380 square meters for warehouses, and 76 square meters for QC. The total number of employees is 36 (including Hebei and Jiangsu), including 5 technical personnel and 2 quality management personnel. The annual revenue is about 50 million yuan. We strictly follow the provisions of the ISO9001 quality management system, ISO14001 environmental management system, and ISO45001 occupational health and safety management system, and carry out strict quality control procedures and inspection assistance procedures for every process from raw material entry to product stationing. We provide guarantees for continuously providing customers with products that meet standards and adhere to an environmentally friendly development strategy.

In the first phase, three production workshops and one kilogram scale pilot plant will be built, with a total of 30 reaction kettles ranging from 100L to 5000L in the production workshop, suitable for chlorination reactions, coupling reactions, format reactions, condensation reactions, asymmetric chiral synthesis, and other reactions; There are a total of 6 100L to 200L reaction kettles and 16 sets of 20L glass bottle reaction sets in the kilogram scale pilot plant, suitable for various reactions, especially anhydrous, anaerobic, and ultra-low temperature reactions;

Dafeng Chemical focuses on the development and production of antibiotic drugs, antiviral drug intermediates, and anti-tumor drug intermediates. Its production capacity is mainly focused on penem intermediates, while tinib and antiviral drug intermediates are produced according to orders.

Our company is a manufacturer of Nast reagents, and through continuous technological improvements, this product has successfully achieved zero emissions of three wastes.